Nvidia CEO Jensen Huang disclosed that the export licence for its H200 artificial intelligence accelerator to Chinese customers is in its final stages of approval by U.S. regulators. Under the agreement, the U.S. government will receive a 25% share of revenues generated from these H200 sales, which Nvidia estimates could be worth up to $50 billion annually if full market access is granted. Huang noted that several major Chinese technology firms, including ByteDance and Alibaba, have already secured preliminary clearance to place purchase orders for hundreds of thousands of units, representing potential contract value of approximately $10 billion in the initial tranche. The final licence is expected to enable shipments as early as Q2, pending reciprocal approval from Chinese authorities.

Representative John Moolenaar, chair of a U.S. House committee, alleged in a recently obtained letter that Nvidia provided technical assistance to China’s DeepSeek division, helping to optimize training workflows for advanced AI models. He claimed Nvidia engineers supported infrastructure design and performance tuning that reduced model training times by up to 40%, and that these same models have since been repurposed for military reconnaissance applications. The bipartisan concern has prompted calls for a formal review of Nvidia’s international research collaborations, with potential implications for future export control policies and company compliance practices.

Nvidia will host its fourth-quarter and full fiscal-year 2026 earnings webcast on February 25, with prepared remarks followed by a Q&A session exclusive to financial analysts and institutional investors. Ahead of the call, CFO Colette Kress will publish written commentary summarizing key metrics, including accelerated growth in the data center segment—responsible for more than 80% of total revenues—and expanding gross margins, which surpassed 68% in the prior quarter. The company also highlighted enterprise adoption of its BioNeMo AI platform by leading biopharma firms and announced a co-innovation laboratory with Eli Lilly to accelerate AI-driven drug discovery, as well as a strategic partnership with Thermo Fisher Scientific to implement autonomous lab infrastructure.

Nvidia’s $20.6 billion acquisition of Groq last year delivered a substantial financial win for early backer Chamath Palihapitiya, who had invested $62.3 million between 2017 and 2018. Despite realizing a more than 300% return on his initial commitment, Palihapitiya revealed that he experienced unexpected emotional downturn following the deal’s announcement. He attributed this to a personal tendency to focus on opportunities for improvement rather than celebrating milestones, noting that his greatest sense of satisfaction comes in the buildup to major corporate events rather than in their aftermath.